Cyramza ® (ramucirumab) injection

10 mg/mL solution

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

CYRAMZA® (ramucirumab): Indications for Use

Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/GEJ adenocarcinoma, NSCLC, mCRC, and HCC.

Detailed Information

Ramucirumab is a human VEGFR-2 antagonist indicated

  • as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy

  • in combination with erlotinib, for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations

  • in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy

    • patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab

  • in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and

  • as a single agent, for the treatment of HCC in patients who have an AFP ≥400 ng/mL and have been treated with sorafenib.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

AFP = alpha-fetoprotein

ALK = anaplastic lymphoma kinase 

EGFR = epidermal growth factor receptor

FDA = Food and Drug Administration 

FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil

GEJ = gastroesophageal junction

HCC = hepatocellular carcinoma

mCRC = metastatic colorectal cancer

NSCLC = non-small cell lung cancer

VEGFR-2 = vascular endothelial growth factor receptor 2

Date of Last Review: May 05, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical